Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition

por Urbanska, Edyta M., Sørensen, Jens B., Melchior, Linea C., Costa, Junia C., Santoni-Rugiu, Eric
Publicado 2020

Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer

por Urbanska, Edyta M., Sørensen, Jens B., Melchior, Linea C., Costa, Junia C., Santoni-Rugiu, Eric
Publicado 2022

Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance

por Santoni-Rugiu, Eric, Melchior, Linea C., Urbanska, Edyta M., Jakobsen, Jan N., de Stricker, Karin, Grauslund, Morten, Sørensen, Jens B.
Publicado 2019

Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-p...

por Rossing, Henrik H, Grauslund, Morten, Urbanska, Edyta M, Melchior, Linea C, Rask, Charlotte K, Costa, Junia C, Skov, Birgit G, Sørensen, Jens Benn, Santoni-Rugiu, Eric
Publicado 2013

Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC

por Urbanska, Edyta M., Grauslund, Morten, Koffeldt, Peter R., Truelsen, Sarah L. B., Löfgren, Johan O., Costa, Junia C., Melchior, Linea C., Sørensen, Jens B., Santoni-Rugiu, Eric
Publicado 2023